With the help of prescription medications and a whole lot of moisturizing, it’s possible to keep dermatitis under control.

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Northwestern University researchers have tested a method to reduce the dreaded nocturnal itch-scratch cycle. Using an ...

A 0.15% once-daily roflumilast cream improved symptoms of atopic dermatitis (AD) across multiple endpoints, according to ...

The AI-driven wearable sensor demonstrates high accuracy in reducing nighttime scratching for atopic dermatitis, improving patient outcomes and sleep quality.

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

Cold weather, dry air, an overactive immune system or our modern lifestyle. The causes may vary, but an increasing number of ...

The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.